AstraZeneca plc vs Levi Strauss & Co. — how do they compare? AstraZeneca plc trades at $158.15 (market cap $248.14B), while Levi Strauss & Co. trades at $22.95 (market cap $8.75B). The key difference: AstraZeneca plc is far larger — about 28.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| AZN | LEVI | |
|---|---|---|
Market Cap | $248.14B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $25.53 |
52-Week Low | $147.06 | $17.92 |
Enterprise Value | $275.41B | $10.07B |
Dividend Yield | 2.01% | 2.81% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →